Successful pregnancy in a patient with chronic myeloid leukemia under treatment with imatinib.
Contraception is recommended during imatinib therapy based on the teratogenicity data in rats. However, patients may become pregnant and here we describe a successful pregnancy and labor without any congenital anomaly in a patient with chronic myeloid leukemia (CML) under treatment with imatinib. The patient had received imatinib for 53 months before she became pregnant, with a complete cytogenetic response achieved after 6 months of therapy and a major molecular response (MMR) after 28 months. CML was in MMR at discovery of pregnancy and the fetus had been exposed to imatinib for 5 weeks. Treatment was discontinued, but MMR persisted during gestation.
Tsuzuki
Motohiro
M
Department of Internal Medicine, Fujita Health University, School of Medicine, Toyoake. mtsuzuki@fujita-hu.ac.jp
Inaguma
Youko
Y
Handa
Kousuke
K
Hasegawa
Akio
A
Yamamoto
Yukiya
Y
Watanabe
Masato
M
Mizuta
Syuichi
S
Maruyama
Fumio
F
Okamoto
Masataka
M
Emi
Nobuhiko
N
D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007231:Infant, Newborn; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000175:diagnosis / Q000188:drug therapy*; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction / Q000379:methods; D016896:Treatment Outcome; D055815:Young Adult
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate